Literature DB >> 15819762

The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas.

G Lebuffe1, E D Dosseh, G Tek, H Tytgat, S Moreno, B Tavernier, B Vallet, C A G Proye.   

Abstract

The peri-operative management of patients undergoing surgery for phaeochromocytoma or paraganglioma with calcium channel blockers (CCB) and their impact on postoperative morbidity and mortality were studied. The medical records of 105 patients undergoing surgery between 1991 and 2002 were analysed retrospectively. In all patients, the calcium channel blocker nicardipine was used for the peri-operative management of haemodynamic changes. Sixty-five patients (61.9%) showed transient intra-operative hypertension. Systolic blood pressure (SBP) > 220 mmHg and SBP > 180 mmHg for > 10 consecutive minutes was observed in 14 (13%) and four patients (2.8%), respectively. SBP < 80 mmHg for > 10 consecutive minutes occurred in 13 patients (12.3%). Eleven patients (10.4%) developed postoperative complications and three patients died (2.8%). The median (range) ICU and hospital length of stay were, respectively, 1 (0-7) day and 10 (2-35) days. The sole use of calcium channel blockers for the peri-operative management of phaeochromocytoma and paraganglioma resection does not prevent all haemodynamic changes; however, its use was associated with a low morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15819762     DOI: 10.1111/j.1365-2044.2005.04156.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  23 in total

Review 1.  [Anesthetic management during pheochromocytoma surgery : Current strategies].

Authors:  B J Nottebaum; H Groeben
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

2.  An interesting case of paraganglioma.

Authors:  Azhar Ali Malik; Ali El Houni; Hassan Gulshad; Syed Elsiah; Suhail Al-Salam
Journal:  BMJ Case Rep       Date:  2009-05-25

3.  Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience.

Authors:  Cyrille Buisset; Carole Guerin; Pierre-Julien Cungi; Mickael Gardette; Nunzia-Cinzia Paladino; David Taïeb; Thomas Cuny; Frederic Castinetti; Frederic Sebag
Journal:  Surg Endosc       Date:  2020-02-18       Impact factor: 4.584

4.  Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients.

Authors:  Laurent Brunaud; Phi-Linh Nguyen-Thi; Eric Mirallie; Marco Raffaelli; Menno Vriens; Pierre-Etienne Theveniaud; Myriam Boutami; Brendan M Finnerty; Wessel M C M Vorselaars; Inne Borel Rinkes; Rocco Bellantone; Celestino Lombardi; Thomas Fahey; Rasa Zarnegar; Laurent Bresler
Journal:  Surg Endosc       Date:  2015-06-20       Impact factor: 4.584

5.  Established endocrine practice.

Authors:  Sam M O'Toole; Morris J Brown; William M Drake
Journal:  Clin Med (Lond)       Date:  2019-01       Impact factor: 2.659

Review 6.  [Preoperative α-receptor block in patients with pheochromocytoma? Against].

Authors:  H Groeben
Journal:  Chirurg       Date:  2012-06       Impact factor: 0.955

Review 7.  Factors affecting the haemodynamic behaviour of patients undergoing pheochromocytoma and paraganglioma removal: A review.

Authors:  Rashmi Ramachandran; Vimi Rewari
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

Review 8.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

Review 9.  Hypertension in Pheochromocytoma and Paraganglioma: Evaluation and Management in Pediatric Patients.

Authors:  Meredith L Seamon; Ikuyo Yamaguchi
Journal:  Curr Hypertens Rep       Date:  2021-05-27       Impact factor: 5.369

Review 10.  Therapeutic goals in patients with pheochromocytoma: a guide to perioperative management.

Authors:  N Azadeh; H Ramakrishna; N L Bhatia; J C Charles; F Mookadam
Journal:  Ir J Med Sci       Date:  2015-12-09       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.